Navigation Links
New Study Shows That Extending Prophylaxis With Clexane / Lovenox,(enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10,Days for Reducing the Risk of Venous Thromboembolism (VTE) in,Acutely ill Medical Patients With Reduced Mobility

ng the standard of care of patients at high risk for VTE and it further establishes enoxaparin as a reference treatment for VTE prophylaxis in acutely ill medical patients".

About EXCLAIM

The EXCLAIM trial is the first international, multicenter, prospective, randomized, double-blind, placebo-controlled study. It enrolled 5,105 acutely-ill patients with recent reduced mobility in 20 countries, comparing extended-duration (28 plus or minus 4 days) venous thromboembolism (VTE) prophylaxis with enoxaparin, a low-molecular-weight heparin (LMWH) with the standard regimen of enoxaparin (10 plus or minus 4 days) for the prophylaxis of VTE.

Patients recently immobilized for up to 3 days with level 1 mobility (total bed rest or sedentary patients) or with level 2 mobility (with bathroom privileges) with age > 75 years or history of VTE or diagnosis of cancer and predefined acute medical illness were randomized to received enoxaparin 40 mg subcutaneously once daily for 10 plus or minus 4 days and were then randomized to receive the same enoxaparin regimen or placebo for an additional 28 plus or minus 4 days.

The steering committee followed the Data Safety Monitoring Board (DSMB) suggestion that in addition to level 1 mobility patients to re-define the inclusion criteria by adding on level 2 mobility patients inclusion criteria : Age >75 years, or prior VTE or diagnosed cancer.

The objective of the Exclaim study was to assess the superiority of enoxaparin prophylaxis given for 28 plus or minus 4 days versus placebo, both following an initial treatment with enoxaparin for 10 plus or minus 4 days, to reduce VTE events

The primary efficacy endpoint was the incidence of asymptomatic deep-vein thrombosis (DVT) detected by routine standardized ultrasonography, symptomatic DVT, symptomatic pulmonary embolism (PE), or fatal PE during the double-blind period. Secondary efficacy endpoints include the incidence of VTE at 3 months and the incidenc
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
3. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. Reaction to Avandia Warnings Stronger Among Internists Than Endocrinologists, According to Study by GfK Market Measures
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
8. Protox Announces Positive Clinical Data from Prostate Cancer Study
9. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
10. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
11. New Phase 3 Study Published in The Lancet Evaluates Efficacy and Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination Therapy in Treatment-Experienced Adults With HIV
Post Your Comments:
(Date:9/23/2014)... Nuclear medicine market is estimated to ... Nuclear are drugs that contain radionuclide-emitting ionization radiation, ... and treat diseases. Increasing incidences of ... and ready availability of radiopharmaceuticals are the major ... awareness and use of SPECT and PET also ...
(Date:9/23/2014)...  SI-BONE, Inc., a medical device company that pioneered ... a minimally invasive surgical (MIS) device indicated for fusion ... U.S. Patent and Trademark Office has awarded the company ... fixation and fusion of bone.  This newly issued patent ... may be placed from one bone across a joint ...
(Date:9/23/2014)... , Sept. 23, 2014   LabStyle Innovations ... Diabetes Management Solution, today announced that it has ... of shares of preferred stock and warrants.  No ... estimated offering expenses, LabStyle expects to secure net ... LabStyle intends to use the ...
Breaking Medicine Technology:Global Nuclear Medicine Market - Growth, Trends & Forecasts (2014-2019) 2SI-BONE, Inc. Strengthens Patent Portfolio with the U.S. Patent and Trademark Office's Issuance of Threaded, Fenestrated Implant Method Patent 2SI-BONE, Inc. Strengthens Patent Portfolio with the U.S. Patent and Trademark Office's Issuance of Threaded, Fenestrated Implant Method Patent 3LabStyle Innovations Closes $4.2 Million Non-Brokered Private Placement Financing 2LabStyle Innovations Closes $4.2 Million Non-Brokered Private Placement Financing 3LabStyle Innovations Closes $4.2 Million Non-Brokered Private Placement Financing 4LabStyle Innovations Closes $4.2 Million Non-Brokered Private Placement Financing 5
... Use of,a low profile PressureWire yields a ... to catheter-derived pressure gradient,(CPG) measurements, according to a ... Vol. 20, Issue 1: 63-65)., The authors ... a,catheter and PressureWire correlated with anatomic stenosis, PressureWire,gradient ...
... 27 Puroast(R) Low Acid Coffee,has conducted both ... its great tasting, gourmet coffee provides symptom relief ... brew. Puroast(R) achieves,this without extractions, substitutes or additives; ... full-bodied taste., Prior chemistry research at University ...
Cached Medicine Technology:Use of PressureWire(R) Yields a More Accurate Assessment of Translesion Pressure Gradients in Peripheral Vasculature, Two New Studies Report 2Use of PressureWire(R) Yields a More Accurate Assessment of Translesion Pressure Gradients in Peripheral Vasculature, Two New Studies Report 3Low Acid Coffee Backed By Scientific Research 2
(Date:9/23/2014)... (September 23, 2014) Both patients and healthcare ... computed tomography (CT) colonography greatly outweighs the potential ... precipitated by false-positive diagnoses, according to a new ... journal Radiology . , Diagnostic tests used ... organ. However, when screening for colorectal cancer with ...
(Date:9/23/2014)... (PRWEB) September 23, 2014 Trevera ... services market. Included are Oracle Managed Services ... Trevera supports all versions of Oracle E-Business Databases ... releases. , Trevera has announced a significant ... that need help with their software technology management, ...
(Date:9/23/2014)... September 23, 2014 The Sloane ... in Singapore and Malaysia providing advanced aesthetic dermatology ... powder to its impressive skin care repertoire. Specially ... skin’s defences against the evil forces of aging, ... glow simultaneously, this new addition is revolutionizing the ...
(Date:9/23/2014)... NC (PRWEB) September 23, 2014 ... a national research university located In the Piedmont ... joined UNCG as co-director of the Center for ... bioanalytical chemistry, comes to UNCG after nearly a ... Northwest National Laboratory, Biological Sciences Division. , ...
(Date:9/23/2014)... HealthDay Reporter MONDAY, ... marches demanding action on climate change, a new study ... the United States may soon exacerbate many existing health ... illnesses are expected to increase as the number of ... Patz, director of the Global Health Institute at the ...
Breaking Medicine News(10 mins):Health News:Patients accept false-positives to achieve diagnostic sensitivity 2Health News:Patients accept false-positives to achieve diagnostic sensitivity 3Health News:Trevera, Inc adds Management Support to Services 2Health News:Trevera, Inc adds Management Support to Services 3Health News:The Sloane Clinic™ introduces a revolutionary BB powder to its impressive skin care repertoire 2Health News:The Sloane Clinic™ introduces a revolutionary BB powder to its impressive skin care repertoire 3Health News:The Sloane Clinic™ introduces a revolutionary BB powder to its impressive skin care repertoire 4Health News:Former Department of Energy Scientist Joins UNCG as Co-director of Biomedical Research Center 2Health News:Health Woes to Worsen Due to Climate Change, Study Warns 2Health News:Health Woes to Worsen Due to Climate Change, Study Warns 3
... development of autism in infants, comparing the behavior of the ... developing normally, has found that the nascent symptoms of the ... communicative babbling are not present at 6 months, but ... of the first year of life. Researchers conducted the ...
... have identified a mechanism used by the tuberculosis bacterium ... a compound that blocks the bacterium,s ability to survive ... to treat tuberculosis. Zhong-Yin Zhang, Ph.D., Robert A. ... and Molecular Biology, and his colleagues revealed the biochemical ...
... , Feb. 15 In just two weeks, online ... helping the organization come in first with more than 49 percent ... the Super Love Sender giving campaign on the Target Facebook® page. ... on February 14, 2010 , invited the online community and ...
... (OHRI) and the University of Ottawa suggests that stem cells ... tissue development. The study, published in Proceedings of the ... researchers think about tissue development, stem cells and cancer. ... all our genes. Certain chemicals and UV light can break ...
... finds , MONDAY, Feb. 15 (HealthDay News) --People who think ... of cigarettes are kidding themselves, a new study shows. , ... Dr. R. Graham Barr, assistant professor of medicine and epidemiology ... report in the Feb. 16 issue of Annals of ...
... effect on squamous cell carcinoma , MONDAY, Feb. 15 ... of NSAID painkillers might help reduce cancer risk, a ... protection against a common skin cancer. , Previous research ... such over-the counter medications as Advil, Motrin, aspirin, Celebrex ...
Cached Medicine News:Health News:Autism's earliest symptoms not evident in children under 6 months 2Health News:Autism's earliest symptoms not evident in children under 6 months 3Health News:Autism's earliest symptoms not evident in children under 6 months 4Health News:IU research team discovers TB disease mechanism and molecule to block it 2Health News:Fans Spread the Love on Target Facebook Page and Help Donate $1 Million to Five Charities 2Health News:Fans Spread the Love on Target Facebook Page and Help Donate $1 Million to Five Charities 3Health News:Fans Spread the Love on Target Facebook Page and Help Donate $1 Million to Five Charities 4Health News:New study suggests stem cells sabotage their own DNA to produce new tissues 2Health News:Cigars, Pipes No 'Healthy' Alternative to Cigarettes 2Health News:Cigars, Pipes No 'Healthy' Alternative to Cigarettes 3Health News:NSAIDs Won't Shield Against Skin Cancer 2Health News:NSAIDs Won't Shield Against Skin Cancer 3
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: